Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Drucker DJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
    Autorzy:
    Finan B; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany. [3] Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
    Yang B; 1] Department of Chemistry, Indiana University, Bloomington, Indiana, USA. [2] Marcadia Biotech, Carmel, Indiana, USA.
    Ottaway N; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
    Smiley DL; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
    Ma T; 1] Department of Chemistry, Indiana University, Bloomington, Indiana, USA. [2] Research Center, Beijing Hanmi Pharm., Beijing, China.
    Clemmensen C; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
    Chabenne J; 1] Department of Chemistry, Indiana University, Bloomington, Indiana, USA. [2] AIT Laboratories, Indianapolis, Indiana, USA.
    Zhang L; Marcadia Biotech, Carmel, Indiana, USA.
    Habegger KM; Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama, USA.
    Fischer K; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
    Campbell JE; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
    Sandoval D; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
    Seeley RJ; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
    Bleicher K; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Uhles S; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Riboulet W; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Funk J; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Hertel C; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Belli S; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Sebokova E; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Conde-Knape K; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Konkar A; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Drucker DJ; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
    Gelfanov V; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
    Pfluger PT; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
    Müller TD; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
    Perez-Tilve D; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
    DiMarchi RD; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
    Tschöp MH; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2015 Jan; Vol. 21 (1), pp. 27-36. Date of Electronic Publication: 2014 Dec 08.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Diabetes Complications/*metabolism
    Diabetes Mellitus, Type 2/*metabolism
    Obesity/*metabolism
    Peptides/*administration & dosage
    Animals ; Blood Glucose/drug effects ; Body Weight/genetics ; Diabetes Complications/drug therapy ; Diabetes Complications/genetics ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/genetics ; Glucagon-Like Peptide 1/agonists ; Glucagon-Like Peptide 1/metabolism ; HEK293 Cells ; Humans ; Insulin/biosynthesis ; Insulin/metabolism ; Mice ; Obesity/drug therapy ; Obesity/genetics ; Peptides/chemical synthesis ; Peptides/metabolism ; Rats ; Receptors, Gastrointestinal Hormone/agonists ; Receptors, Gastrointestinal Hormone/metabolism ; Receptors, Glucagon/agonists ; Receptors, Glucagon/metabolism ; Rodentia
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Metabolic disease puts up a fight: are diet and exercise helpful for the heart?
    Autorzy:
    Lovshin JA; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
    Drucker DJ
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2013 Oct; Vol. 19 (10), pp. 1216-7.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Diet*
    Exercise*
    Diabetes Mellitus, Type 2/*physiopathology
    Heart/*physiopathology
    Diabetes Mellitus, Type 2/diet therapy ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/therapeutic use ; Weight Loss
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Liraglutide.
    Autorzy:
    Drucker DJ; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada. d.drucker@utoronto.ca
    Dritselis A
    Kirkpatrick P
    Pokaż więcej
    Źródło:
    Nature reviews. Drug discovery [Nat Rev Drug Discov] 2010 Apr; Vol. 9 (4), pp. 267-8.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Diabetes Mellitus, Type 2/*drug therapy
    Glucagon-Like Peptide 1/*analogs & derivatives
    Hypoglycemic Agents/*therapeutic use
    Adult ; Drug Approval ; Glucagon-Like Peptide 1/pharmacology ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/pharmacology ; Liraglutide ; Randomized Controlled Trials as Topic ; United States ; United States Food and Drug Administration
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Normalization of obesity-associated insulin resistance through immunotherapy.
    Autorzy:
    Winer S; Department of Pediatrics & Immunology, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
    Chan Y
    Paltser G
    Truong D
    Tsui H
    Bahrami J
    Dorfman R
    Wang Y
    Zielenski J
    Mastronardi F
    Maezawa Y
    Drucker DJ
    Engleman E
    Winer D
    Dosch HM
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2009 Aug; Vol. 15 (8), pp. 921-9. Date of Electronic Publication: 2009 Jul 26.
    Typ publikacji:
    Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Insulin Resistance/*immunology
    Obesity/*complications
    Obesity/*therapy
    Adipose Tissue/immunology ; Adipose Tissue/metabolism ; Adipose Tissue/pathology ; Animals ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/pathology ; CD4-Positive T-Lymphocytes/physiology ; Cell Separation ; Glucose/metabolism ; Homeodomain Proteins/genetics ; Homeostasis/immunology ; Immunotherapy/methods ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, Obese ; Obesity/immunology ; Obesity/pathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Autorzy:
    Drucker DJ; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. d.drucker@utoronto.ca
    Nauck MA
    Pokaż więcej
    Źródło:
    Lancet (London, England) [Lancet] 2006 Nov 11; Vol. 368 (9548), pp. 1696-705.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Review
    MeSH Terms:
    Adenosine Deaminase Inhibitors*
    Dipeptidyl-Peptidase IV Inhibitors*
    Hypoglycemic Agents*/administration & dosage
    Hypoglycemic Agents*/adverse effects
    Hypoglycemic Agents*/therapeutic use
    Adamantane/*analogs & derivatives
    Diabetes Mellitus, Type 2/*drug therapy
    Glucagon-Like Peptide 1/*analogs & derivatives
    Glucagon-Like Peptide 1/*physiology
    Glycoproteins/*antagonists & inhibitors
    Peptides/*therapeutic use
    Pyrazines/*therapeutic use
    Receptors, Glucagon/*agonists
    Triazoles/*therapeutic use
    Venoms/*therapeutic use
    Adamantane/administration & dosage ; Adamantane/adverse effects ; Adamantane/therapeutic use ; Clinical Trials as Topic ; Dipeptidyl Peptidase 4 ; Drug Administration Schedule ; Exenatide ; Glucagon-Like Peptide 1/administration & dosage ; Glucagon-Like Peptide 1/adverse effects ; Glucagon-Like Peptide 1/biosynthesis ; Glucagon-Like Peptide 1/classification ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor ; Humans ; Liraglutide ; Nitriles ; Peptides/administration & dosage ; Peptides/adverse effects ; Pyrazines/administration & dosage ; Pyrazines/adverse effects ; Pyrrolidines ; Sitagliptin Phosphate ; Triazoles/administration & dosage ; Triazoles/adverse effects ; Venoms/administration & dosage ; Venoms/adverse effects ; Vildagliptin
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies